Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed at early stages of
normal development and in various cancers including ALK-positive anaplastic large cell …

Autophagy has been described as harboring a dual role in cancer development and
therapy. Depending on the context, it can exert either pro-survival or pro-death functions …

Drug resistance is a critical factor responsible for the recurrence of non-small cell lung
cancer (NSCLC). Previous studies suggest that curcumin acts as a chemosensitizer and …

Many patients diagnosed with acute myeloid leukemia (AML) relapse within two years of the
initial remission. The biology of AML relapse is incompletely understood, although cancer …

Crizotinib (CRIZO) has been widely employed to treat non‐small‐cell lung cancer. However,
hepatic inflammatory injury is the major toxicity of CRIZO, which limits its clinical application …

In ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), a small subset of cancer stem-
like (or RR) cells characterized by high Myc expression have been identified. We …

Background: Crizotinib is a microtubule-related protein-4-anaplastic lymphoma kinase
(EML4-ALK) multi-target tyrosine kinase inhibitor applied in the treatment of ALK-rearranged …

Chromosomal rearrangements leading to the relocation of proto-oncogenes into
transcription-active regions are found in various types of tumors. In particular, the transfer of …

Cancer in childhood ages have significant differences from adult cancer in the incidence
rate, type and location of cancer, pathophysiology, progression of tumor, management plan …